Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other 1Gastrointestinal 1

Conditions

Multiple Myeloma 62Neoplasms 7Neoplasms, Plasma Cell 6Recurrence 5Hematologic Neoplasms 4Renal Insufficiency 3Paraproteinemias 3Lymphoma 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Blood Protein Disorders 2Purpura 1Prostatic Neoplasms 1Neoplasm, Residual 1Nausea 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Macroglossia 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphadenopathy 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1

Interventions

Octreotide 6Irinotecan 6Loperamide 5Probiotics 3Leucovorin 3Fluorouracil 3Fecal Microbiota Transplantation 3Calcium Aluminosilicate 3maltodextrin 2telotristat ethyl 1shosaiko-to 1lanreotide 1isatuximab 1ceterizine hydrochloride 1capivasertib 1cabazitaxel 1bile acid binding proteins 1XRP6258 1Theophylline 1Temozolomide 1Surveys and Questionnaires 1Sulfasalazine 1Sugars 1Standard of Care 1Raloxifene Hydrochloride 1Radiation 1Prednisone 1PHY 906 1Oxaliplatin 1Long-Term Synaptic Depression 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diarrhea × isatuximab × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡